PepsiCo, Inc. (NASDAQ:PEP) is making bold operational shifts across its global portfolio as it navigates shifting demand ...

Guidance was raised from $7.60–$7.90 EPS to $7.75–$8, now inclusive of tariffs. Margin expansion guidance increased from "upside to the midpoint" to a specified "150 to 200 basis points" for the year.

Researchers have found in a 3-year phase 3 trial that palopegteriparatide (TransCon PTH) showed sustained improvements in ...

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.

A Memphis police officer ran a red light, causing a car crash. The officer had an expired drivers license. Here's what else ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

A trial testing a nerve-sparing (NeuroSAFE) technique in radical prostatectomy may improve patient-reported outcomes.

Investing.com -- Cogent Biosciences, Inc. (NASDAQ: COGT) stock surged 10% after announcing positive top-line results from its SUMMIT trial of bezuclastinib in patients with non-advanced systemic ...

PSFF consistently delivers lower risk and some upside, justifying its lower returns versus the S&P 500. Read more on PSFF ETF ...

July 10, 2025The Simply Good Foods Company reports earnings inline with expectations. Reported EPS is $0.51 EPS, expectations ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

Background Restarting direct oral anticoagulants (DOACs) after a serious bleeding event in patients with atrial fibrillation ...